Research Partner receives a nice chunk of funding Aug 9/2022: A new grant from the
Weston Family Foundation through the Weston Brain Institute will support the research and development of a vaccine against neurodegenerative diseases caused by the misfolded protein alpha-synuclein (A-syn). This project features a collaborative team of neuroscientists from across Canada, led by Dr.
Neil Cashman, a researcher at UBC’s Djavad Mowafaghian Centre for Brain Health and Chief Scientific Officer at
ProMIS Neurosciences.
About the Collaborative Team Neil Cashman, MD is a clinician-scientist at the University of British Columbia’s Djavad Mowafaghian Centre for Brain Health and Founder/Chief Scientific Officer at ProMIS Neurosciences.
Scott Napper, PhD is a Research Scientist at the
Vaccine and Infectious Disease Organization (VIDO) and is also a Professor of Biochemistry, Microbiology, and Immunology at the University of Saskatchewan. VIDO is one of the most advanced vaccine development research centers in the world with a proven track-record for the development and commercialization of vaccines (eight of its vaccines have been sold commercially). The Napper lab has over 15 years of research experience in vaccine development.
Marco Prado, PhD is the Canada Research Chair in Neurochemistry of Dementia and Professor of Anatomy & Cell Biology / Physiology and Pharmacology / Robarts Research Institute, at the University of Western Ontario.
Joel Watts, PhD, is the Canada Research Chair in Protein Misfolding Disorders and is an Associate Professor within the Department of Biochemistry and the Tanz Centre for Research in Neurodegenerative Diseases at the University of Toronto
__________________________________________________________________________
August 19 /2022: Four flagship research centres at the University of Saskatchewan (USask) uniquely equipped to keep Canada at the forefront internationally in vaccine development, imaging science, sustainable water management and monitoring space weather have been awarded nearly $170 million.
$53.9 million is for VIDO: VIDO is a global leader in infectious disease research, and vaccine development for humans and animals. The organization has played a key role in Canada’s response to the COVID-19 pandemic. To deliver on its role as Canada’s Centre for Pandemic Research, VIDO is expanding its world-class facilities to include vaccine manufacturing, new animal housing and upgrading to containment level 4. VIDO facilities enable researchers from Canada and abroad to study new and re-emerging infectious diseases, increasingly of zoonotic origins, and develop and manufacture vaccines.